24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination (BTFC)
Primary Purpose
Glaucoma
Status
Completed
Phase
Phase 4
Locations
Greece
Study Type
Interventional
Intervention
Drug: bimatoprost/timolol fixed combination AM
Bimatoprost/timolol fixed combination dosed PM
Sponsored by

About this trial
This is an interventional treatment trial for Glaucoma focused on measuring 24-hour IOP control
Eligibility Criteria
Inclusion Criteria:
- The patient is suffering from XFG (if the patient has bilateral XFG, both eyes will be treated, but the worse eye will be selected for the statistical analysis)
- Patient is older than 39 years and younger than 85 years
- Patient is able and willing to participate in the study for the whole duration of the follow up. Will sign the consent form.
- At screening the untreated IOP at 10:00 (± 1 hr) is greater than 25 mm Hg and lower than 40 mm Hg
- After bimatoprost run-in therapy the treated IOP at 10:00 (± 1 hr) is greater than 19 mm Hg
Sites / Locations
- Glaucoma Unit, 1st University Department of Ophthalmology
- Glaucoma Unit, 1st University Dept of Ophthalmology
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Bimatoprost/Timolol AM therapy
Bimatoprost/Timolol PM therapy
Arm Description
Outcomes
Primary Outcome Measures
Mean 24-hour IOP
Secondary Outcome Measures
Side effects with medications
Full Information
NCT ID
NCT00486486
First Posted
June 13, 2007
Last Updated
May 9, 2014
Sponsor
Aristotle University Of Thessaloniki
1. Study Identification
Unique Protocol Identification Number
NCT00486486
Brief Title
24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination
Acronym
BTFC
Official Title
A 3-month, 4-centre, Crossover, Double-masked Study Investigating the 24-hour Intraocular Pressure Control With the Bimatoprost/Timolol Fixed Combination Dosed Morning, or Evening in Subjects With Exfoliative Glaucoma
Study Type
Interventional
2. Study Status
Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
March 2007 (undefined)
Primary Completion Date
May 2008 (Actual)
Study Completion Date
July 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Aristotle University Of Thessaloniki
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The objective of this crossover, randomized, placebo controlled, double-masked study is to compare the short-term (12 weeks) mean 24-hour IOP control and safety of the new fixed combination (bimatoprost/timolol, BTFC) given PM with placebo once in the morning, versus BTFC given AM with placebo once in the evening versus bimatoprost given in the evening in patients with exfoliative glaucoma (XFG).
Detailed Description
PRIMARY STUDY OBJECTIVES
To show that the mean 24-hour IOP control obtained with BTFC (morning or evening) is statistically better to that with bimatoprost monotherapy given once on the evening.
To demonstrate that the fixed combination will provide a significantly better IOP control in the morning when dosed in the evening.
To test whether the mean 24-hour IOP control obtained with BTFC given once in the evening may be statistically better to that with BTFC given once in the morning.
To show whether there will be less 24-hour fluctuation of IOP with the evening dosing of BTFC.
STUDY POPULATION
Consecutive newly-diagnosed, or suitably washed-out patients with exfoliative glaucoma (XFG) who exhibit a mean untreated IOP greater than 25 mm Hg at baseline (10:00).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glaucoma
Keywords
24-hour IOP control
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Bimatoprost/Timolol AM therapy
Arm Type
Active Comparator
Arm Title
Bimatoprost/Timolol PM therapy
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Drug: bimatoprost/timolol fixed combination AM
Intervention Description
3-month chronic dosing in the morning
Intervention Type
Drug
Intervention Name(s)
Bimatoprost/timolol fixed combination dosed PM
Intervention Description
Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months
Primary Outcome Measure Information:
Title
Mean 24-hour IOP
Time Frame
3 months of therapy
Secondary Outcome Measure Information:
Title
Side effects with medications
Time Frame
3 months of therapy
10. Eligibility
Sex
All
Minimum Age & Unit of Time
39 Years
Maximum Age & Unit of Time
81 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The patient is suffering from XFG (if the patient has bilateral XFG, both eyes will be treated, but the worse eye will be selected for the statistical analysis)
Patient is older than 39 years and younger than 85 years
Patient is able and willing to participate in the study for the whole duration of the follow up. Will sign the consent form.
At screening the untreated IOP at 10:00 (± 1 hr) is greater than 25 mm Hg and lower than 40 mm Hg
After bimatoprost run-in therapy the treated IOP at 10:00 (± 1 hr) is greater than 19 mm Hg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anastasios Konstas, MD, PhD
Organizational Affiliation
Head of the Glaucoma Unit
Official's Role
Principal Investigator
Facility Information:
Facility Name
Glaucoma Unit, 1st University Department of Ophthalmology
City
Thessaloniki
ZIP/Postal Code
546 36
Country
Greece
Facility Name
Glaucoma Unit, 1st University Dept of Ophthalmology
City
Thessaloniki
Country
Greece
12. IPD Sharing Statement
Citations:
PubMed Identifier
19825835
Citation
Konstas AG, Hollo G, Mikropoulos D, Tsironi S, Haidich AB, Embeslidis T, Georgiadou I, Irkec M, Melamed S. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol. 2010 Feb;94(2):209-13. doi: 10.1136/bjo.2008.155317. Epub 2009 Oct 12.
Results Reference
derived
Learn more about this trial
24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination
We'll reach out to this number within 24 hrs